Table 3.
Data are presented as the percentage of cycles for which patients experienced toxicity. Total number of cycles for each regimen is as follows: 103 gemcitabine-only and 111 gemcitabine + docetaxel for the uterine group; 104 gemcitabine-only and 95 gemcitabine + docetaxel for the nonuterine group; and 207 gemcitabine-only and 206 gemcitabine + docetaxel for all sarcomas.
Abbreviations: D, docetaxel; G, gemcitabine.